Crinetics Pharmaceuticals SEC Filings

Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported a series of estate and charitable planning moves involving gifts of 1,937,600 shares of common stock on May 29, 2026. The transactions are coded as bona fide gifts, with reported prices of $0.0000 per share, indicating no sale proceeds.

The gifts include transfers among multiple family trusts, a charitable remainder trust, and his spouse, with the filing noting that he disclaims beneficial ownership of certain trust-held shares except for his pecuniary interest. Following these transactions, he continues to hold significant positions, including 626,978 shares directly and 439,005 shares indirectly through Family Trust 1.

T. Rowe Price Associates, Inc. filed an amendment reporting beneficial ownership of 5,355,011 shares of Crinetics Pharmaceuticals common stock, representing 5.1% of the class. The filing lists sole voting power over 5,352,428 shares and sole dispositive power over 5,355,011 shares. The filing also includes a declarative statement denying beneficial ownership.

Wellington Management Group LLP amended its Schedule 13G/A to report 7.79% beneficial ownership of Crinetics Pharmaceuticals, Inc. common stock. The filing lists shared voting power and shared dispositive power across related Wellington entities, including 8,157,204 shares of shared dispositive power as reported on cover pages.

Driehaus Capital Management LLC amends its Schedule 13G/A to report beneficial ownership of Crinetics Pharmaceuticals common stock. As of March 31, 2026, Driehaus held 6,395,922 shares, representing 6.11% of the class, down from 7.54% as of December 31, 2023. The filing states these shares are held on a fully discretionary basis for multiple clients and that voting and dispositive power is shared by Driehaus. The amendment was signed on May 15, 2026.

Crinetics Pharmaceuticals reported first‑quarter 2026 results that reflect its transition to a commercial-stage company following the U.S. launch of PALSONIFY for acromegaly. Total revenue was $10.7 million, driven by $10.3 million of PALSONIFY net product sales and $0.4 million of collaboration and license revenue.

The company recorded a net loss of $127.8 million as it continued heavy investment in research and development of paltusotine, atumelnant and other endocrine programs, along with commercial and administrative infrastructure. R&D expenses were $100.1 million and selling, general and administrative expenses were $50.8 million.

Crinetics strengthened its balance sheet with a January 2026 underwritten offering of 8.8 million shares, generating approximately $380 million of net proceeds. As of March 31, 2026, cash, cash equivalents and investment securities totaled $1.3 billion, which management believes will fund operations for at least 12 months.

Crinetics Pharmaceuticals reported first-quarter 2026 revenue of $10.7 million, driven by $10.3 million in net product revenue from the U.S. launch of PALSONIFY for acromegaly. Management highlighted strong prescriber uptake, with 232 enrollment forms and 263 unique healthcare providers within the first two quarters of launch, and about 70% of patients on reimbursed therapy.

R&D expenses rose to $100.1 million and selling, general and administrative costs to $50.8 million, reflecting expansion as a commercial-stage company. Net loss widened to $127.8 million. Cash, cash equivalents and investment securities were $1.3 billion, supported by $380 million of net proceeds from a January 2026 equity offering. The company reaffirmed 2026 GAAP operating expense guidance of $600–650 million and non-GAAP operating expense guidance of $480–520 million, and outlined progress on its global PALSONIFY strategy and late-stage pipeline including atumelnant.

CORINUS PHARMACEUTICALS insider sales reported via Form 144: the filing discloses open-market dispositions totaling 120,408 shares across four reported 10b5-1 transactions in March–April 2026. The filing also lists an exercise of 8,985 stock options on 05/04/2026 and 500 RSUs from 03/15/2025.

Vanguard Capital Management reports beneficial ownership of 5,440,646 shares (5.19%) of Crinetics Pharmaceuticals Inc common stock. The filing shows sole dispositive power over 5,440,646 shares and sole voting power for 766,711 shares. The Schedule 13G was signed by Ashley Grim on 04/29/2026.

Crinetics Pharmaceuticals, Inc. filed its Form 10-K reporting operations for the fiscal year ended December 31, 2025. The company is a commercial-stage endocrine-focused biopharma with an FDA-approved product, PALSONIFY (paltusotine), and a diversified pipeline including atumelnant and the NDC candidate CRN09682.

The filing highlights FDA approval of PALSONIFY on September 25, 2025 and U.S. commercial availability in October 2025, ongoing global regulatory activity including a CHMP positive opinion in February 2026, multiple active Phase 1–3 programs, third-party manufacturing and distribution arrangements, and intellectual property estate with patent expirations estimated through the mid-2040s.

Crinetics Pharmaceuticals is holding its 2026 annual shareholder meeting on June 18, 2026 via live webcast. Shareholders of record as of April 20, 2026, when 105,439,535 common shares were outstanding, can vote.

Three Class II directors are up for election, PricewaterhouseCoopers LLP is proposed as the new independent auditor for 2026, and shareholders will cast an advisory “say‑on‑pay” vote on named executive officer compensation. The eight‑member board is majority independent, led by an independent chair, with specialized audit, compensation, nominating, R&D, and commercialization committees. Non‑employee directors receive cash retainers and equity awards under a structured program, and several institutional investors each hold over 7% of the stock.